189956-41-0

Basic information

• Product Name: 2-cyclobutoxyacetic acid
• Synonyms: 2-cyclobutoxyacetic acid
• CAS NO: 189956-41-0
• Molecular Formula: C₆H₁₀O₃
• Molecular Weight: 130
• Mol File: 189956-41-0.mol

Chemical Properties

• Boiling Point: 278.6±13.0 °C(Predicted)
• Appearance: /
• Density: 1.17±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 3.55±0.10(Predicted)
• CAS DataBase Reference: 2-cyclobutoxyacetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-cyclobutoxyacetic acid(189956-41-0)
• EPA Substance Registry System: 2-cyclobutoxyacetic acid(189956-41-0)

Safety Data

• Hazardous Substances Data: 189956-41-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-cyclobutoxyacetic acid is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows for the development of new drugs with improved efficacy and reduced side effects.
Used in Agrochemical Industry:
2-cyclobutoxyacetic acid is used as a building block in the production of agrochemicals, such as herbicides and plant growth regulators. Its potential in this field is currently being studied, with the aim of developing more effective and environmentally friendly products.
Used in Organic Synthesis:
2-cyclobutoxyacetic acid is used as a versatile building block in organic synthesis, enabling the creation of a wide range of chemical compounds with diverse applications. Its cyclobutane ring provides unique structural features that can be exploited in the synthesis of novel molecules.
Used in Environmental Research:
2-cyclobutoxyacetic acid is studied for its low toxicity and minimal bioaccumulation potential. Further research is needed to fully understand its environmental impact and explore its potential use in eco-friendly applications.

Upstream product

• 2919-23-5 cyclobutanol 
• 79-08-3 bromoacetic acid 
• 3926-62-3 sodium monochloroacetic acid 

Relevant articles and documents

Identification of a Hydroxypyrimidinone Compound (21) as a Potent APJ Receptor Agonist for the Potential Treatment of Heart Failure

This paper describes our continued efforts in the area of small-molecule apelin receptor agonists. Recently disclosed compound 2 showed an acceptable metabolic stability but demonstrated monodemethylation of the dimethoxyphenyl group to generate atropisomer metabolites in vitro. In this article, we extended the structure–activity relationship at the C2 position that led to the identification of potent pyrazole analogues with excellent metabolic stability. Due to the increased polarity at C2, the permeability for these compounds decreased. Further adjustment of the polarity by replacing the N1 2,6-dimethoxyphenyl group with a 2,6-diethylphenyl group and reoptimization for the potency of the C5 pyrroloamides resulted in potent compounds with improved permeability. Compound 21 displayed excellent pharmacokinetic profiles in rat, monkey, and dog models and robust pharmacodynamic efficacy in the rodent heart failure model. Compound 21 also showed an acceptable safety profile in preclinical toxicology studies and was selected as a backup development candidate for the program.

COMPOUNDS, COMPOSITIONS AND METHODS

The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or prodrug thereof, and methods of making and using thereof.

CETP INHIBITORS

Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. I

SAR in the alkoxy lactone series: The discovery of DFP, a potent and orally active COX-2 inhibitor

Extensive SAR has been established in the alkoxy lactone series and this has lead to the discovery of DFP (5,5-dimethyl-3-(2-propoxy)-4- methanesulfonylphenyl)-2(5H)-furanone), a potent COX-2 inhibitor exhibiting in vivo efficacy in all models studied.